Compare Match Group Inc (MTCH) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs TG Therapeutics Inc — how do they compare? Match Group Inc trades at $36.82 (market cap $8.45B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Match Group Inc and TG Therapeutics Inc are close in size by market cap, and Match Group Inc pays a 2.17% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MTCH | TGTX | |
|---|---|---|
Market Cap | $8.45B | $7.64B |
Sector | Media | Health |
52-Week High | $41.24 | $59.06 |
52-Week Low | $28.90 | $26.94 |
Enterprise Value | $11.42B | $7.84B |
Dividend Yield | 2.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Match Group (MTCH) trades at $36.63, down 0.27% with bearish technical signals despite reasonable valuation metrics (P/E 13.05, P/S 2.66). Recent Q2 2026 earnings missed revenue estimates with $853 million (down 1% YoY) though Tinder engagement improved and Hinge grew 22% YoY. Operating cash flow remains strong at $1.08 billion in 2025, but high debt ($3.85 billion) and negative shareholder equity pose balance sheet concerns.
The outlook is mixed: analyst consensus is Buy (53% of 32 analysts) with $42.33 price target (16% upside), but near-term revenue pressure and Tinder's sluggish performance create headwinds. Investment opportunity lies in Hinge's international expansion and Tinder turnaround potential, while risks include execution missteps, competitive threats, and macroeconomic sensitivity affecting dating app usage.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
